Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
MacroGenics
Incyte Corporation
Novelty Nobility, Inc.
Hangzhou DAC Biotechnology Co., Ltd.
Pfizer
Hoffmann-La Roche
University of Virginia
Incyte Corporation
Theratechnologies
Sotio Biotech Inc.
AstraZeneca
Xencor, Inc.
Pfizer
University of Florida
Fate Therapeutics
Xencor, Inc.
Xencor, Inc.
Opna Bio LLC
Genocea Biosciences, Inc.
AbbVie
AbbVie
Incyte Corporation
Incyte Corporation
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Abramson Cancer Center at Penn Medicine
Celgene
University of Wisconsin, Madison
Santa Maria Biotherapeutics
Virginia Commonwealth University
University of Southern California
Northwestern University
ImmunoGen, Inc.
Yale University
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Novartis
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center